 |
|
Nordic collaboration gives new insights into adjuvant chemotherapy
September 22, 2003Denmark, Copenhagen: A major clinical collaboration by Scandinavian cancer specialists has shown that patients with advanced colon cancer could well gain a small but worthwhile improvement in five-year overall survival if they were treated with chemotherapy as well as surgery - provided the drugs were given in optimum conditions and to the most appropriate patients.
An analysis of a set of randomised trials[1] involving patients in Denmark, Norway and Sweden has been able to provide new insights into the effects of chemotherapy in colorectal cancer, ECCO 12 - the European Cancer Conference heard today (Thursday 25 September).
Prof. Bengt Glimelius, a professor and consultant at the University Hospital in Uppsala and the University Hospital Karolinska Sjukhuset in Stockholm, explained to a news briefing that by collaborating across borders and carrying out a joint analysis the investigators were able to see how adjuvant therapy was likely to work when used as part of routine care for patients with stage II and III colon and rectal cancer.
The analysis, which constituted the largest clinical study to be presented at the ECCO 12 meeting, demonstrated that among 2,223 patients, the 708 patients with colon cancer stage III had a five-year survival of 49% for those treated by surgery alone, but 56% for those given chemotherapy as well. "Although this difference was not statistically significant, it has helped to highlight the need for chemotherapy to be given under optimum conditions and has provided vital evidence about which are the patients most likely to benefit," he said.
For example, one of the Norwegian contributing trials of 425[2] patients with stage II and III colon and rectum cancer, while showing no overall statistically different survival (68% controls, 72% chemotherapy arm), did show a statistically significant benefit for chemotherapy for patients with stage III colon cancer (48% controls, 65% chemotherapy arm). The investigators concluded that colon cancer patients with lymph nodes metastases should continue to receive chemotherapy as standard treatment.
Prof Glimelius said that the Nordic collaboration differed from previous clinical studies because some of the trials had a very pragmatic design - they assessed the usefulness of a treatment in the 'real world' closer to routine hospital care than generally is the case in clinical trials. "Pragmatic trials may, for instance, have less strict rules about which patients to include or exclude, be more liberal about randomisation and how quickly chemotherapy should be started and for how long it should be given," he said.
"In this study some patients had quite a delay before starting chemotherapy, even though it was stressed how important it is to initiate treatment as soon as possible when there are fewer tumour cells to kill. It is possible that we did not show any clear statistically significant difference overall because of this longer than average delay due to the trial's pragmatic design. Also, several patients had only four months of treatment, and that may be too short. Importantly, the results tell us to look carefully within our trials to see what may be hidden within the overall results - for example, how results may differ between colon or rectal cancer patients, how benefits may differ between different stages of the disease or between men and women."
He said that the Nordic trial was of great general importance. It was big, it was done in 'real world' conditions with less patient selection than generally is the case. It was also running at a time (the 1990s) when there was not always the closest possible collaboration between specialties.
"What this trial has told us that is of key importance is that we must optimise care by ensuring the closest collaboration between specialities and the optimum conditions for patients, and that cross-border international collaborations are the best way to learn these lessons quickly and efficiently. Small differences in survival can translate into many lives saved in common cancers," he concluded.
(ends)
[1] Abstract no: 1066. Prof Bengt Glimelius (Thursday 25 September, 09.30 hrs CET, FECS/EJC award presentations session).
[2] Abstract no: 1084 Professor Olav Dahl (Thursday 25 September, 10.45 CET Colorectal cancer session).
WordMason
Colon Cancer Current Events and Colon Cancer News RSSA Simple Blood Test for Colon Cancer
People are often reluctant to undergo a routine but painful colonoscopy ― but the consequences can be fatal. According to the American Cancer Society, colon cancer is the third most common cancer found in American men and women and kills about 50,000 Americans every year.
Adalimumab may reduce health-care costs for Crohn's disease patients
Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD). IBD occurs most frequently in people in their late teens and twenties. There have been cases in children as young as two years old and in older adults in their seventies and eighties; men and women have an equal chance of getting the disease.
Washington University scientists first to sequence genome of cancer patient
For the first time, scientists have decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots.
Minority patients discouraged from cancer screening by negative messages
New behavioral science research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, found that constantly emphasizing the negative consequences of a lack of cancer screening among minorities can actually make them less likely to go for screening.
Sibling study could lead to better treatments for inherited form of colon cancer
Researchers at Huntsman Cancer Institute (HCI) believe they may be one step closer to understanding how certain forms of colon cancer develop.
What's the role of beta-catenin in colorectal cancers?
Beta-catenin, a central molecule of the Wnt-signaling pathway was previously known to involve in the tumorigenesis of various gastrointestinal cancers such as gastric cancer and colon cancer.
Jefferson Department of Surgery announces new pancreas tumor registry
Charles J. Yeo, M.D., Samuel D. Gross Professor and Chair, Department of Surgery at Jefferson Medical College of Thomas Jefferson University, announces the establishment of the new Jefferson Pancreas Tumor Registry (JPTR).
Supercomputer provides massive computational boost to biomedical research at TGen
In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout.
Novel marker of colon cancer
Colon cancer ranks second of all gastrointestinal malignant tumors, it is one of the leading causes of cancer-related deaths worldwide.
Mayo Clinic physicians estimate new, tiny, super-sensitive probe could cut colon polyp removal in half
Based on results of a landmark study, researchers at Mayo Clinic's Florida campus see a future in which virtual biopsies will eliminate the need to remove colon polyps that are not cancerous or will not morph into the disease.
More Colon Cancer Current Events and Colon Cancer News Articles
 | Living With Colon Cancer: Beating the Odds by Eliza Wood Livingston Despite the efforts of Katie Couric to draw attention to the importance of colonoscopy screening for the detection of colon cancer, this cancer still does not receive the publicity devoted to breast, lung, and prostate cancer. Yet colorectal cancer is the third most common malignancy in the world and is the second leading cause of death from cancer next to lung cancer. As a result of the silence... |
 | Colon Cancer Answers by Dr. Bruce A. Feinberg One of the greatest failures of public health practices and policy in America is the mismanagement of colon cancer. Despite the fact that colon cancer is 90 percent preventable through safe, accessible, cost-effective screening tests, this terrible disease remains the second leading cause of cancer death. Each year, more than 150,000 Americans will die -- an unnecessary and costly human... |
 | Understanding Colon Cancer by A. Richard, M.D., F.A.C.P. Adrouny For decades, while other cancers grabbed the headlines, colorectal cancer was quietly ignored. The lifetime risk of colorectal cancer in the general population is 2.5 to 5 percent. This means that twenty-five to fifty out of one thousand people will be stricken by this disease. Although data show that in America colorectal cancer incidence and mortality have been waning in recent decades,... |
 | What Your Doctor May Not Tell You About(TM) Colorectal Cancer: New Tests, New Treatments, New Hope (What Your Doctor May Not Tell You About...) by Mark Bennett Pochapin Colorectal cancer (cancer of the colon and/or rectum) is the second leading cancer killer in the United States - over 50,000 men and women die from it each year. This is a particularly alarming statistic since it is also one of the most preventable and most treatable forms of cancer. In fact, it is estimated that over one-third of colorectal cancer deaths could easily be avoided. But most people,... |
 | 50 Ways to Prevent Colon Cancer by M. Sara Rosenthal |
 | American Cancer Society's Complete Guide to Colorectal Caner by American Cancer Society Don't die of embarrassment--get informed about colorectal cancer Although colorectal cancer is the third most common cancer found in men and women, you may be unaware of your risk and don't know what you can do to prevent this serious disease. You may be too embarrassed to ask your doctor about changes in your bowel habits or get screened for colorectal cancer. American Cancer Society's Complete... |
 | The Colon Cancer Survivors' Guide: Living Stronger, Longer by Curtis Pesmen Based on his award-winning series of Esquire magazine articles on his own survival of colon cancer, the author shows how a person diagnosed with cancer stops becoming a patient and starts becoming a survivor. Above all, it offers advice on the healing of scars, both physical and emotional, how to leave cancer behind, and how to move confidently... |
 | Positive Options for Colorectal Cancer: Self-Help and Treatment by Carol Ann Larson Colorectal cancer develops slowly over a period of several years, undetected, usually as polyps. It is a preventable and treatable disease if caught in time, yet most know little about how to read its symptoms. Written for the layperson, this book covers all the uncomfortable questions and answers about the disease, from prevention and warning signs, to screening and diagnosis techniques, to... |
 | What To Do If You Get Colon Cancer: A Specialist Helps You Take Charge and Make Informed Choices by Paul Miskovitz, Marian Betancourt From initial diagnosis to the latest treatments, this encouraging, authoritative guide explores everything you need to know to make informed choices about colon cancer care. You'll learn how colon cancer develops, what to expect from diagnostic tests, and how to choose the best doctors and treatment centers. Here's invaluable information on: Which treatment options work best for different phases... |
 | Colon Cancer & the Polyps Connection by Stephen Fisher The first and only book exploring the causes, cures and prevention of colorectal cancer. Includes terms, procedures, treatments, medical facts and data from American Cancer Society and National Cancer... |
| © 2008 BrightSurf.com |